News / Finance
WhisperfromWallStreet.com "Morning Gainers - Talbots, Inc.,TLB - AVI Biopharma, Inc.,AVII - Majesco Entertainment Co.,COOL
Talbots Inc. - AVI BioPharma, Inc. - Majesco Entertainment Co.
Talbots, Inc.,TLB
Talbots Inc. has been improving merchandise and may sell its J. Jill chain sooner than expected, an analyst said Wednesday, upgrading shares of the women's apparel retailer.
Lazard Capital Markets analyst Todd Slater upgraded the stock to "Buy" from "Hold" and said several suitors are interested in J. Jill, according to Talbots management.
The company believes it will sell J. Jill -- also a women's apparel chain -- within the next year, but Slater said a deal may happen sooner than later.
Meanwhile this year, Talbots will improve merchandise, Slater said, which should entice customers back to stores and boost sales.
"Unlike some of its competitors who clearly have the wrong product, Talbots already has product heading in the right direction," Slater wrote in a client note.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
AVI Biopharma, Inc.,AVII
AVI BioPharma, Inc., a developer of RNA-based drugs, today announced that Peter Sazani, Ph.D., Executive Director of Preclinical Development, is presenting an overview of AVI-4658 today at the at the TIDES Oligonucleotide and Peptide Technology and Product Development Conference taking place in Las Vegas, Nevada.
Dr. Sazani's presentation, which is part of the conference's 'Innovation Showcase,' will feature an overview of AVI-4658, the Company's RNA therapeutic in development for treatment of Duchenne muscular dystrophy (DMD). AVI-4658 is a phosphorodiamidate morpholino oligomer (PMO) drug designed to skip exon 51 of the dystrophin gene, allowing for restoration of the reading frame in the mRNA sequence. Results from a Phase 1 single dose escalation study of AVI-4658 testing the effect of intramuscular (IM) showed that injection of the drug into the muscles of a series of DMD patients successfully induced dystrophin production in each patient.
---
Majesco Entertainment Co.,COOL
Majesco Entertainment Company, an innovative provider of video games for the mass market, will announce financial results for its fiscal second quarter 2009 ended April 30, 2009 on Monday, June 15, 2009 after U.S. market hours.
Senior management will host a conference call to discuss fiscal second quarter 2009 financial results on June 15, 2009 at 4:30 p.m. ET. To access the conference call, please dial in approximately 10 minutes prior to the start of the conference call.
A live webcast of the conference call will be available on the "Investor Relations" section of the Company's corporate Web site at http://www.majescoentertainment.com.
A replay of the conference call will be available via telephone for seven days beginning approximately two hours after the call through June 22, 2009. U.S. participants can access the replay by dialing 1-877-344-7529 and international participants can dial 1-412-317-0088. The access code for the replay is 431058. A webcast of the conference call will be archived on the Company's Web site for 90 days.
----
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
